<rp id="nt1u6"><optgroup id="nt1u6"></optgroup></rp>

      <ruby id="nt1u6"><nav id="nt1u6"></nav></ruby>

      <rt id="nt1u6"><meter id="nt1u6"></meter></rt>

      1. <tt id="nt1u6"><noscript id="nt1u6"></noscript></tt>

        <rt id="nt1u6"><optgroup id="nt1u6"></optgroup></rt>
        <source id="nt1u6"></source>
        <b id="nt1u6"><noscript id="nt1u6"></noscript></b><source id="nt1u6"></source>

        A POWERFUL RESEARCH AND
        DEVELOPMENT ENGINE

        Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

        • Phase 1 trials

          Phase 1 Trials

          CEMIPLIMAB*

          PD-1 Antibody
          Cancer

          REGN3767

          LAG-3 Antibody
          Cancer

          REGN1979

          CD20xCD3 Antibody
          Cancer

          REGN4018*

          MUC16xCD3 Antibody
          Cancer

          REGN4659

          CTLA4 Antibody
          Cancer

          REGN5458*

          BCMAxCD3 Antibody
          Cancer

          REGN3048-3051

          Middle East Respiratory Coronavirus Antibody
          MERS-CoV infection

          REGN4461

          LEPR Antibody
          Lipodystrophy and obesity

          REGN5713-5714-5715

          Betv1 Antibody
          Birch Allergy
        • Phase 2 trials

          Phase 2 Trials

          CEMIPLIMAB*

          PD-1 Antibody
          Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
          REGN1979
          CD20xCD3 Antibody
          Relapsed / refractory follicular lymphoma

          DUPILUMAB*

          IL-4R Antibody
          Grass allergy, peanut allergy

          SARILUMAB*

          IL-6R Antibody
          Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

          REGN1908-1909

          Fel d 1 Antibody
          Cat allergy

          REGN3500*

          IL-33 Antibody
          Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis

          REGN5069

          GFRα3 Antibody
          Osteoarthritis knee pain

          GARETOSMAB

          Activin A Antibody
          Fibrodysplasia Ossificans Progressiva (FOP)

          EVINACUMAB

          ANGPTL-3 Antibody
          Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

          POZELIMAB

          C5 Antibody
          Paroxysmal nocturnal hemoglobinuria
        • Phase 3 trials

          Phase 3 Trials

          AFLIBERCEPT
          VEGF-Trap
          Non-proliferative diabetic retinopathy (NPDR) without DME

          ALIROCUMAB*

          PCSK9 Antibody
          Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

          CEMIPLIMAB*

          PD-1 Antibody
          Non-small cell lung cancer, cervical cancer

          REGN-EB3

          Ebola Virus Antibody
          Ebola virus infection

          DUPILUMAB*

          IL-4R Antibody
          Atopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPD

          SARILUMAB*

          IL-6R Antibody
          Polymyalgia rheumatica, giant cell arteritis

          EVINACUMAB

          ANGPTL-3 Antibody
          Homozygous familial hypercholesterolemia (HoFH)

          FASINUMAB?

          NGF Antibody
          Chronic pain from osteoarthritis of the knee or hip

        Trials Footnotes

        * in collaboration with Sanofi

        ? in collaboration with Teva and Mitsubishi Tanabe

        This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

        国产区露脸视频